UMELISA EGF®: a useful tool for research and diagnosis

Authors

Keywords:

UMELISA EGF®, CIMAvax-EGF®, non-small cell lung cancer (NSCLC), epidermal growth factor (EGF), efficacy biomarker

Abstract

Introduction: The Cuban vaccine CIMAvax-EGF® is useful in non-small cell lung cancer (NSCLC) patients with high serum concentrations of epidermal growth factor ([EGF]), the current predictor of response. However, the discrimination between healthy individuals and NSCLC patients by [EGF], which determines the diagnostic accuracy and efficacy of the biomarker, is questionable. The controversy occurs mainly due to methodological deficiencies in its estimation.

Methods: This work presents a new methodology for the quantification of human serum EGF, aimed at controlling the factors causing bias and variability in the estimates. The approach includes the development of the quantification kit UMELISA EGF®, the standardization of sera separation, and the normalization of [sEGF] regarding platelets count, as well as its interpretation.

Results: The study revealed that patients and controls differ only by circulating EGF, measured in sera separated 1h after phlebotomy ([EGF]1h) and not by the total EGF in platelets, estimated in sera collected 4h after blood draw ([EGF]4h). Several variables related to EGF, with discriminatory power (diagnostic value) and potentiality as a biomarker, were identified. Specially circulating ([EGF]1h) and platelet-retained EGF ([EGF]4h-[EGF]1h), both normalized by platelets count, discriminate better patients from healthy controls than circulating or total EGF. Conclusions: the greater discriminatory capacity of the normalized variables indicates their more direct relationship with the biology of the tumor, compared to the current efficacy biomarker; as well as its better performance in predicting the response to anti-EGF/EGFR therapies and to the CIMAvax-EGF® in particular; which, together with the safety and low cost of the UMELISA EGF® test, suggests its possible use in the screening and early diagnosis of the disease in populations at risk.

Downloads

Download data is not yet available.

Downloads

Published

2023-04-22

How to Cite

González Pérez, I., Castells Martínez, E. M., del Valle García, R., León Monzón, K., Cáceres Lavernia, H. H., Melchor Rodríguez, A., … Camilo Rodríguez, P. (2023). UMELISA EGF®: a useful tool for research and diagnosis. Anales De La Academia De Ciencias De Cuba, 13(2), e1265. Retrieved from https://revistaccuba.sld.cu/index.php/revacc/article/view/1265

Issue

Vol. 13 No. 2: April-June 2023 (Issue in Progress)

Section

Biomedical sciences

License

The journal Anales de la Academia de Ciencias de Cuba protects copyright, and operates with a Creative Commons License 4.0 (Creative Commons Attribution-NonCommercial License 4.0). By publishing in it, authors allow themselves to copy, reproduce, distribute, publicly communicate their work and generate derivative works, as long as the original author is cited and acknowledged. They do not allow, however, the use of the original work for commercial or lucrative purposes.

The authors authorize the publication of their writings, retaining the authorship rights, and assigning and transferring to the magazine all the rights protected by the intellectual property laws that govern in Cuba, which imply editing to disseminate the work.

Authors may establish additional agreements for the non-exclusive distribution of the version of the work published in the journal (for example, placing it in an institutional repository or publishing it in a book), with recognition of having been first published in this journal.

To learn more, see https://creativecommons.org